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Abstract
Introduction Efforts are ongoing to determine the significance
of unclassified variants (UVs) in the breast cancer susceptibility
genes  BRCA1/BRCA2, but no study has systematically
assessed whether women carrying the suspected deleterious
UVs have characteristics commonly seen among women
carrying known deleterious or disease-causing mutations in
BRCA1/BRCA2.
Methods We sequenced BRCA1/BRCA2 in 1,469 population-
based female breast cancer patients diagnosed between the
ages of 20 and 49 years. We used existing literature to classify
variants into known deleterious mutations, polymorphic variants,
and UVs. The UVs were further classified as high risk or low risk
based on five methods: allele frequency, Polyphen algorithm,
sequence conservation, Grantham matrix scores, and a
combination of the Grantham matrix score and sequence
conservation. Furthermore, we examined whether patients who
carry the variants classified as high risk using these methods
have risk characteristics similar to patients with known
deleterious BRCA1/BRCA2 mutations (early age at diagnosis,
family history of breast cancer or ovarian cancer, and negative
estrogen receptor/progesterone receptor).
Results We identified 262 distinct BRCA1/BRCA2 variants,
including 147 UVs, in our study population. The BRCA1 UV
carriers, but not the BRCA2 UV carriers, who were classified as
high risk using each classification method were more similar to
the deleterious mutation carriers with respect to family history
than those carriers classified as low risk. For example, the odds
ratio of having a first-degree family history for the high-risk
women classified using Polyphen was 3.39 (95% confidence
interval = 1.16 to 9.94) compared with normal/polymorphic
BRCA1  carriers. The corresponding odds ratio of low-risk
women was 1.53 (95% confidence interval = 1.07 to 2.18). The
odds ratio for high-risk women defined by allele frequency was
2.00 (95% confidence interval = 1.14 to 3.51), and that of low-
risk women was 1.30 (95% confidence interval = 0.87 to 1.93).
Conclusion The results suggest that the five classification
methods yielded similar results. Polyphen was particularly better
at isolating BRCA1 UV carriers likely to have a family history of
breast cancer or ovarian cancer, and may therefore help to
classify BRCA1 UVs. Our study suggests that these methods
may not be as successful in classifying BRCA2 UVs.
BIC = Breast Cancer Information Core; DDCV = definitely disease-causing variant; ER = estrogen receptor; GMS = Grantham matrix score; HFUV 
= high-frequency unclassified variant; LFUV = low-frequency unclassified variant; PR = progesterone receptor; UV = unclassified variant.Breast Cancer Research    Vol 10 No 1    Lee et al.
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Introduction
In the early 1990s the breast cancer susceptibility genes
BRCA1 and BRCA2 were identified through linkage analyses
[1-4]. BRCA1, located on chromosome 17q12-q21, consists
of 24 exons encoding a protein of 1,863 amino acids and is
involved in DNA repair [5,6], in transcription [7,8], and in the
cell cycle checkpoint in DNA damage response [9-11].
BRCA2, located on chromosome 13q12-q13, consists of 27
exons encoding a protein of 3,418 amino acids and is also
involved in DNA repair [12-15], but its role in transcription and
the cell cycle checkpoint is less clear [16].
Since the discovery of the BRCA1 and BRCA2 genes, a total
of 1,643 and 1,856 distinct variants have been reported in the
Breast Cancer Information Core (BIC) Database for BRCA1
and BRCA2 as of April 2007 [17]. Among these variants,
frameshift mutations, nonsense mutations, splice variants and
a few well-documented missense mutations are considered
deleterious [18], while synonymous variants have been con-
sidered benign or polymorphic. A large number of missense or
intronic variants of BRCA1 or BRCA2 remain of unknown sig-
nificance. The proportion of breast cancer patients who carry
these unclassified variants (UVs) is about 9% [19]. Given that
only 2% to 3% of breast cancer patients have deleterious
mutations in BRCA1 or BRCA2 [20], understanding the clin-
ical significance of this relatively large number of UVs is of
great importance.
Functional studies can provide direct insight into whether the
UV has biological consequences, but few of these studies
have been performed [21,22]. Other approaches have been
applied to classify the significance of UVs, including compari-
sons of allele frequencies [18], algorithms such as Polyphen
(see Materials and methods) [23], examination of sequence
conservation across species [24-26], and characterization of
the physicochemical nature of the amino acid substitutions
(Grantham matrix scores) [26,27]. A combination approach of
the sequence conservation and Grantham matrix score meth-
ods was applied to classify a large number of UVs [26]. No
systematic evaluation, however, has been conducted to deter-
mine whether patients who carry the variants classified as high
risk using these methods have similar characteristics as
patients with known deleterious BRCA1/BRCA2 mutations,
which would suggest that these high-risk UVs are deleterious.
Breast cancer patients with a known deleterious mutation in
BRCA1/BRCA2  are more likely to have a family history of
breast cancer or ovarian cancer [28] and an earlier age of
diagnosis than noncarrier patients [18,29]. In addition,
BRCA1 deleterious mutation carriers are more likely to have
estrogen receptor (ER)-negative and progesterone receptor
(PR)-negative tumors than women without such mutations
[29]. In the current analyses, we classified BRCA1/BRCA2
UVs using the four methods listed above and a combination of
the Grantham matrix scores and sequence conservation. We
then evaluated the validity and usefulness of each method by
comparing the risk categories of UV carriers with respect to




The data collection methods for this study have been
described previously [30]. In brief, female patients diagnosed
with histologically confirmed first primary invasive breast can-
cer were identified through the Los Angeles County Cancer
Surveillance Program, a population-based Surveillance, Epi-
demiology and End Results registry supported by the State of
California and the National Cancer Institute. Eligible cases
were US born and English speaking, white (including His-
panic) or African-American, aged 20 to 49 years at diagnosis,
and Los Angeles County residents at diagnosis. A total of
2,882 eligible cases were identified (2,534 whites and 348
African-Americans) between February 1998 and May 2003.
Recruitment of African-Americans began after the initiation of
the study with eligible African-American cases diagnosed from
January 2000 to May 2003.
Among the 2,882 potentially eligible cases, 1,794 (62%) were
interviewed (1,585 white, 209 African-American). Reasons for
nonparticipation were patient refusal (n = 428), no longer a
resident of Los Angeles County (n = 37), not located (n = 88),
death (n = 38), serious illness or disability (n = 18), physician
refusal (n = 50), or inability to schedule the interview within 18
months of diagnosis (n = 429). The study was approved by the
Institutional Review Board of the University of Southern Cali-
fornia. All participants provided written informed consent.
Data and blood specimen collection
An inperson interview was completed using a modified version
of the structured questionnaire used in the Women's Contra-
ceptive and Reproductive Experiences Study [31]. The ques-
tionnaire included detailed information on demographic
characteristics, family history of breast cancer or ovarian can-
cer, ethnic origin, and environmental factors such as oral con-
traceptive use, reproductive history, alcohol use, smoking
history, and radiation exposure. We obtained information up to
the date of breast cancer diagnosis. Blood specimens were
collected from 1,519 participants (85%) and were transported
to the Norris Cancer Center Genetics Core Laboratory in Sty-
rofoam containers on frozen ice packs. For the first 50 sam-
ples the buffy coat was immediately extracted and stored, and
for the remaining samples we stored whole blood.
Sequencing of BRCA1 and BRCA2 genes
All BRCA1 and BRCA2 exons (except BRCA1 exons 1 and 4
and BRCA2 exon 1) as well as all exon–intron boundaries
were sequenced. Exon 1 was not sequenced for either gene
because it is located upstream of the translation start site inAvailable online http://breast-cancer-research.com/content/10/1/R19
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both genes. BRCA1 exon 4 was not sequenced because it is
not found in the normal BRCA1 mRNA transcript.
DNA extraction, amplification and sequencing were carried
out in the USC Genomics Core Laboratory using a protocol
similar to that previously described [32]. The detailed proce-
dures are described in the supplemental methods (see Addi-
tional File 1). We sequenced BRCA1/BRCA2  genes for
1,469 out of 1,519 blood specimens. We were unable to
sequence the remaining 50 specimens due to insufficient
DNA.
Thirty-three randomly selected, blinded samples were rese-
quenced for quality control purposes. The discordance rate
was 0.19%: 16 discordant sequencing results out of the total
8,646 variant sites sequenced (262 variant sites for each of
the 33 samples). In addition, 166 subjects who had nonin-
formative sequencing results on one or more variant sites were
resequenced or genotyped using the TaqMan assay (for
BRCA2 I2490T, N372H, and N991D) as previously
described [33].
Epidemiologic and histologic variables
Age at diagnosis was categorized as <35 years, 35 to 39
years, 40 to 44 years, and 45 to 49 years. We classified
women based on their family history of breast cancer or ovar-
ian cancer as follows: one or more breast cancer or ovarian
cancer patients among their first-degree relatives (mother and
full sisters); no first-degree family history of breast cancer or
ovarian cancer but one or more breast cancer or ovarian can-
cer patients among their second-degree relatives (mother's or
father's full sisters, and grandmothers); no first-degree or sec-
ond-degree relatives diagnosed with breast cancer or ovarian
cancer; and an unknown first-degree family history. We con-
sidered unknown second-degree family history as no family
history.
The ER and PR status of the breast cancer was obtained by
abstracting pathology reports collected by the Los Angeles
County Cancer Surveillance Program. Among the 1,469 sub-
jects, ER/PR information was available for 1,216 patients
(83%). For the ER/PR analyses, we excluded 63 patients who
had borderline ER/PR status and 101 patients whose ER/PR
status was +/- or -/+, leaving 1,052 patients with a +/+ or -/-
receptor status.
Classification of BRCA1/BRCA2 mutation status
We classified each identified BRCA1/BRCA2 variant accord-
ing to its predicted functional and biological significance as
follows: definitely disease-causing variants (DDCVs), includ-
ing frameshift mutations, nonsense mutations, splice variants
that were previously reported to affect splicing or were located
at the exon/intron boundary, and missense variants that were
previously shown to be deleterious; UVs, including inframe
deletion/insertions, intronic variants that might affect splicing
by creating a splice donor/acceptor site, variants next to the
exon/intron boundary, and most missense variants; and benign
polymorphic variants, including synonymous variants, intronic
variants that are unlikely to affect splicing, and a few missense
mutations that were reported to be benign. (See Additional
File 2 for a list of all variants identified in this study, with their
classification and the reasons and references for such
classification.)
Further classification of BRCA1 and BRCA2 unclassified 
variants
We further classified BRCA1/BRCA2 UVs using the following
methods.
Classification based on allele frequency
We divided the UVs into high-frequency unclassified variants
(HFUVs) and low-frequency unclassified variants (LFUVs)
depending on the minor allele frequency (≥ 1% versus <1%)
in each ethnic group (142 African-Americans, 222 Hispanic
whites, 1,105 non-Hispanic whites). If the minor allele fre-
quency is ≥ 1% in one or more ethnic groups, the UV was cat-
egorized as a HFUV. This categorization was based on the
assumption that variants with high frequency would be less
likely to be disease causing compared with variants of very low
frequency.
Polyphen-based classification
Polyphen is an algorithm that classifies the functional effect of
each missense variant into three categories (probably damag-
ing, possibly damaging, and benign) [34]. This classification is
based on the chemical characteristics of the substitution site
(for example, disulfide bond, transmembrane region), the align-
ment of homologous sequences, and protein three-dimen-
sional structures [23]. UVs other than missense variants are
not classified by Polyphen. The Polyphen classification in this
report is based on access to the algorithm in March 2007.
Classification based on sequence conservation across 
mammalian species
A variant that occurs at a site with high-degree conservation is
considered more likely to be deleterious than a variant occur-
ring at a site with low-degree conservation [35]. We selected
only mammals for cross-species comparisons of the BRCA1/
BRCA2 sequences, since the function of these two proteins
in mammals could be different from that in other animals. We
selected all mammalian species whose BRCA1/BRCA2
sequences were reported in the National Center for Biotech-
nology Information gene database or whose complete coding
sequences were reported in the National Center for Biotech-
nology Information nucleotide sequence database. Ten spe-
cies for BRCA1 and five species for BRCA2 met these criteria
(see Additional File 2). Sequence alignment was performed
using the Clustal W method [36] and the MegAlign software
(DNASTAR, Inc., Madison, WI, USA).Breast Cancer Research    Vol 10 No 1    Lee et al.
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We classified BRCA1/BRCA2 missense variants into three
categories (high conservation, moderate conservation, and
low conservation) depending on the number of the species
that had a different amino acid from that of the human at the
site of variation. For each UV in BRCA1 we considered differ-
ences in zero or one species out of the 10 examined to repre-
sent high conservation, differences in two or three species to
represent moderate conservation, and differences in four or
more species to represent low conservation. For BRCA2 we
compared sequences of five species: no difference in all five
species was considered high conservation, one or two differ-
ences were considered moderate conservation, and three or
more differences were considered low conservation.
Classification based on the Grantham matrix score
The Grantham matrix score (GMS) is a composite measure of
the degree of amino acid substitution, taking into account the
side-chain composition, polarity, and molecular volume of the
two amino acids [27]. We dichotomized the GMS at 60, a cri-
terion previously used to define neutral missense variants [26].
Integration of sequence conservation and the Grantham 
matrix score
We adopted a previously reported classification scheme inte-
grating the sequence conservation and the GMS [26]. Briefly,
if the variant was located at a fully conserved site or led to a
nonconservative substitution at a conserved site, it was con-
sidered deleterious. If the variant amino acid is observed in
other species or led to conservative substitution, it was con-
sidered neutral. See Additional File 1 for further details.
Classification of women who carry unclassified variants 
in BRCA1/BRCA2
Each subject was categorized hierarchically based on their
BRCA1 and BRCA2 mutation status (Figure 1). This means
that anyone successfully classified by the first criterion would
not be further classified by the criteria that followed. This hier-
archical classification leads to mutually exclusive categories
(DDCV carriers, UV carriers, normal/polymorphic carriers, and
patients with unknown mutation status) as follows. First, a
patient was classified as a DDCV carrier if she had one or
more of the DDCV(s). Second, if the patient did not belong to
the DDCV group and had a noninformative result at any of the
identified DDCV sites, she was classified as unknown. Third, if
the patient did not belong to these first two categories and
carried one or more of the UVs, she was classified as a UV car-
rier. Fourth, if the patient did not belong to the first three cate-
gories and any of the sequencing results at the identified UV
sites was noninformative for the subject, she was classified as
unknown. Finally, if the patient did not belong to any of the pre-
ceding categories, she was classified as a polymorphic or nor-
mal genotype carrier.
UV carriers were further classified hierarchically into mutually
exclusive categories of high risk, moderate risk, low risk, and
unknown risk according to the various UV classifications. For
example, when applying the allele frequency method, a UV car-
rier was classified as high risk if the subject carried one or
more of the LFUVs, as unknown risk if any of the sequencing
results at the LFUV site was noninformative for the subject, as
low risk if the subject carried one or more of the HFUVs, and
as unknown risk if any of the sequencing results at the HFUV
site was noninformative for the subject. Classification using
Figure 1
Illustration of the classification scheme of BRCA1/BRCA2 variants Illustration of the classification scheme of BRCA1/BRCA2 variants. DDCV, definitely disease-causing variant; UV, unclassified variant.Available online http://breast-cancer-research.com/content/10/1/R19
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other methods such as Polyphen, the GMS, or sequence con-
servation followed the same hierarchical logic.
Six BRCA1 UV carriers and six BRCA2 UV carriers with a
possible splice variant or in-frame deletion were categorized
only by allele frequency since Polyphen, the GMS, and the
integrated GMS/sequence conservation methods are not
applicable to these splice variants and in-frame deletions.
These women were therefore excluded from the analyses
using Polyphen, the GMS, sequence conservation, and the
integrated GMS/sequence conservation methods.
Statistical analyses
We compared the UV classification methods of allele fre-
quency, Polyphen, sequence conservation, and the GMS by
examining the pairwise joint distribution of BRCA1/BRCA2
UVs as classified using each method. Tests for a linear trend
in the GMS across the three UV categories classified using
Polyphen and the sequence conservation method were con-
ducted in linear regression models. The mean GMS across
two UV categories using allele frequency was compared by t
test. We assessed whether UV classifications using allele fre-
quency, Polyphen and the sequence conservation methods
are correlated using an exact Mantel–Haenszel chi-square
test.
We performed case–case analyses to examine the associa-
tion between BRCA1 or BRCA2 carrier status categorized
using each method (exposure variable) and outcome variables
(clinical and disease characteristics). Case–case analyses
were conducted using polychotomous logistic regression
when the outcome variable was family history of breast cancer
or ovarian cancer. The association with the ER/PR status was
analyzed using logistic regression. We used linear regression
where the outcome variable was age at diagnosis of breast
cancer. When examining BRCA1, results were adjusted for
the BRCA2 mutation status (DDCV, non-DDCV, unknown),
and vice versa.
All reported P values are two-sided. The SAS 9.1 package
was used for all analyses (SAS Institute, Cary, NC, USA).
Results
A total of 105 distinct BRCA1 variants (including 32 DDCVs)
and 157 distinct BRCA2 variants (including 27 DDCVs) were
identified in the 1,469 breast cancer patients (see Additional
File 3). Among these distinct variants, 22 BRCA1 variants and
30 BRCA2 variants had not been reported in the BIC as of
April 2007.
Correlated classifications using various approaches
Classification using the Polyphen algorithm appeared to be
correlated both with the GMS and the conservation method:
BRCA1/BRCA2  missense variants classified as high risk
(probably damaging) using Polyphen had a higher mean GMS
than those classified as low risk (benign missense variants)
(Table 1). BRCA1/BRCA2  missense variants classified as
benign missense variants using Polyphen were generally
located at sites with low degree of sequence conservation,
while probably damaging missense variants tended to be
located in highly conserved regions (Table 2). The GMS, how-
ever, was not strongly correlated with level of conservation
across species (Table 1). Given the small number of HFUVs of
BRCA1/BRCA2, the classification using the allele frequency
method seemed to be associated with the classifications
using other methods, although not all of these analyses
achieved statistical significance.
Classification of case patients with regard to BRCA1 or 
BRCA2 status
Among the 1,469 case patients in this study, 61 women car-
ried a BRCA1 DDCV and 34 women carried a BRCA2 DDCV.
Among the remaining women, 307 women and 860 women
were UV carriers in BRCA1 and in BRCA2, respectively.
Classification of BRCA1/BRCA2 status in relation to 
epidemiologic and histologic outcome variables
Family history of breast cancer or ovarian cancer
The BRCA1 DDCV carriers were substantially more likely to
have a first-degree family history of breast cancer or ovarian
cancer than the normal/polymorphic BRCA1 carriers (odds
ratio = 11.3; Table 3) after adjusting for the BRCA2 mutation
status. The UV carriers were also significantly, although to a
smaller extent, more likely to have a first-degree family history
than normal/polymorphic BRCA1 carriers (odds ratio = 1.54).
The high-risk UV carriers were, in general, significantly more
likely to have a first-degree family history of breast cancer or
ovarian cancer than normal/polymorphic women, whereas the
low-risk UV carriers were not. For example, the high-risk UV
carriers identified using the allele frequency (LFUV) or
Polyphen (probably damaging) methods were more likely to
have a first-degree family history (odds ratio = 2.00 and 3.39,
respectively) than normal/polymorphic BRCA1 carriers.
A similar trend was observed using the sequence conservation
or the GMS method, although differences between the cate-
gories of UV carriers were smaller. The integrated method of
the GMS/sequence conservation classified only nine subjects
as high risk, and their odds ratio was not different from that of
the women who remained unclassified.
The BRCA2 DDCV carriers were also at a higher risk of having
a first-degree family history of breast cancer or ovarian cancer
compared with the normal/polymorphic BRCA2  carriers
(odds ratio = 3.69) after adjusting for BRCA1 mutation status.
The association was weaker than that of BRCA1 DDCV carri-
ers. Regardless of the classification method, the high-risk UV
carriers were not statistically significantly different from the
normal/polymorphic BRCA2 carriers with regard to family his-
tory (Table 3).Breast Cancer Research    Vol 10 No 1    Lee et al.
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Age at diagnosis and estrogen receptor/progesterone 
receptor status
As expected, compared with the carriers of normal/polymor-
phic BRCA1, the BRCA1 DDCV carriers had a much earlier
age at diagnosis (by 4.1 years; P < 0.001) and more ER/PR-
negative tumors (odds ratio = 7.24, 95% confidence interval
= 3.56 to 14.7). Case patients with high-risk UVs, however,
did not have such characteristics regardless of the method of
UV classification. The BRCA2 DDCV or UV status was not
associated with early age at diagnosis or with ER/PR negativ-
ity (data not shown).
Comparisons of the classifications using the methods in 
this study and the Breast Cancer Information Core
The recent update of the BIC includes the assessment of the
clinical importance of each variant. This assessment is based
on several criteria, including epidemiological, segregation, and
co-occurrence data. Among the UVs in this study, one BRCA1
UV (IVS5-11T > G) was classified as clinically important
whereas three BRCA1 UVs and 19 BRCA2 UVs were classi-
fied as clinically nonimportant. IVS5-11T > G was classified as
a high-risk UV using allele frequency (LFUV). Since this variant
is not a missense variant, other methods were not applicable.
Table 4 shows how each UV that was considered nonimpor-
tant in the BIC was classified by the five UV classification
methods. The allele frequency and the GMS method classified
a large number of variants as high risk that were considered
nonimportant by the BIC, particularly for BRCA2. In contrast,
Polyphen and the conservation methods classified few such
variants as high risk.
Discussion
In the present study of young breast cancer patients, we iden-
tified numerous variants in BRCA1/BRCA2  by direct
sequencing, including 22 BRCA1 and 30 BRCA2 new vari-
ants that have not been reported in the BIC as of April 2007.
Table 1
Mean Grantham matrix score of BRCA1/BRCA2 variants (unclassified variants) according to classification using allele frequency, 
Polyphen, and sequence conservation
Gene Classification method Level Number of variants Grantham matrix score
Mean Standard deviation Minimum Maximum
BRCA1 Allele frequency Low risk (HFUV) 5 38.2 20.7 10 56
High risk (LFUV) 39 69.7 45.0 10 194
P value (t test) 0.13
Polyphen Benign missense 28 55.0 42.3 10 180
Possible damaging 9 65.3 29.4 10 101
Probably damaging 7 111.9 40.5 71 194
P for trenda 0.002
Sequence conservation Low 14 53.6 44.7 10 180
Moderate 14 70.9 43.5 10 154
High 16 73.0 44.2 10 194
P for trenda 0.24
BRCA2 Allele frequency Low risk (HFUV) 18 67.7 39.7 5 149
High risk (LFUV) 77 87.0 52.9 10 205
P value (t test) 0.15
Polyphen Benign missense 44 58.1 41.3 5 194
Possible-damaging 25 91.4 41.7 21 180
Probably-damaging 26 118.3 52.3 27 205
P for trenda <0.001
Sequence conservation Low 33 71.5 49.4 10 194
Moderate 29 92.1 55.6 5 205
High 33 87.5 47.8 21 194
P for trenda 0.20
LFUV, low-frequency unclassified variant; HFUV, high-frequency unclassified variant. aBased on the F test in a linear regression model.Available online http://breast-cancer-research.com/content/10/1/R19
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We applied various methods to classify 44 BRCA1 UVs and
95 BRCA2 UVs. To our knowledge, our study is the first to
attempt to classify a large number of BRCA1/BRCA2 UVs
identified in population-based breast cancer patients and to
correlate these variants with outcome variables.
We found that classifications of BRCA1/BRCA2 UVs using
the various classification methods in general agree with each
other (Table 1 and Table 2). In particular, Polyphen seemed to
be correlated with the GMS and with sequence conservation,
which is expected given the composite nature of this algo-
rithm. This intercorrelation supports the reliability of the classi-
fication methods.
In general, the BRCA1 UV carriers classified as high risk were
at increased risk of having a family history of breast cancer or
ovarian cancer. Family history has been considered a powerful
tool in classifying UVs [37], and having a first-degree relative
with breast cancer increases the breast cancer risk about two-
fold [38]. The odds ratio for the high-risk UV group was high-
est when using Polyphen, suggesting that the algorithm is
better for the purpose of describing high-risk variants when
using family history as a measure of true risk. We cannot
exclude, however, the possibility that more stringent cutoff
points to define the high-risk group using other methods (that
is, high-degree conservation defined as no cross-species
variation; or high GMS defined as >100) might increase the
odds ratio estimates of the high-risk group. In this study, we
did not have sufficient numbers of UV carriers to investigate
this possibility.
Considering that the high-risk BRCA1 UV carriers classified
using all of the classification methods were at a higher risk of
having a family cancer history (either statistically significantly
or nonsignificantly), we expected to observe similar trends
using age of diagnosis or the ER/PR status as the outcome
variables. This observation, however, did not occur. The nar-
row age range of our study subjects, all of whom were under
age 50 at diagnosis, could have limited the study power. For
analyses of the ER/PR status, our exclusion of about 30% of
women because of missing, borderline, or mixed (-/+ or +/-)
ER/PR status may have limited the statistical power. Alterna-
tively, it is possible that only truncating mutations (resulting in
a complete loss of BRCA1 functions), but not missense vari-
ants (retaining part of its ability; for example, the ability to inter-
act with certain proteins), of BRCA1 lead to the high density
of ER/PR-negative tumors.
For BRCA2, it is unclear why none of the classification meth-
ods identified high-risk UV carriers when family history was
used as the measure of true risk. One explanation could be the
fact that BRCA2 DDCV carriers themselves did not have such
a high odds ratio as seen for BRCA1 DDCV carriers. The
BRCA2 DDCV carrier status was also not associated with age
at diagnosis in this study, again possibly because all of our
subjects were younger than 50 years and the age at diagnosis
Table 2
Joint distribution of BRCA1/BRCA2 variants (unclassified variants) according to classification using allele frequency, Polyphen, and 
sequence conservation
Gene Classification method Level Conservation Frequency
Low Moderate High HFUV LFUV
BRCA1 Frequency Low risk (HFUV) 3 1 1
High risk (LFUV) 11 13 15
P valuea 0.26
Polyphen Benign missense 12 10 6 4 24
Possible damaging 2 3 4 1 8
Probably damaging 0 1 6 0 7
P valuea 0.002 0.39
BRCA2 Frequency Low risk (HFUV) 10 6 2
High risk (LFUV) 23 23 31
P valuea 0.018
Polyphen Benign missense 26 11 7 11 33
Possible damaging 5 10 10 5 20
Probably damaging 2 8 16 2 24
P valuea <0.001 0.089
LFUV, low-frequency unclassified variant; HFUV, high-frequency unclassified variant. aBased on the exact Mantel–Haenszel chi-square test.Breast Cancer Research    Vol 10 No 1    Lee et al.
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Table 3
Association between family history of breast cancer or ovarian cancer and BRCA1 or BRCA2 status of the breast cancer patients
Mutation/unclassified variant status None First degree Second degree
na na OR (95% CI)b P valuec na OR (95% CI)b P valuec
BRCA1d
Normal/polymorphism (reference) 600 166 1 282 1
Definitely disease-causing variant 13 35 11.3 (5.73 to 22.5) <0.001 11 1.89 (0.83 to 4.31) 0.13
Unclassified variant 156 67 1.54 (1.10 to 2.15) 0.012 75 1.02 (0.74 to 1.39) 0.90
Unclassified variant classification using
Allele frequency
High risk (LFUV) 39 21 2.00 (1.14 to 3.51) 0.016 22 1.20 (0.70 to 2.06) 0.52
Low risk (HFUV) 115 42 1.30 (0.87 to 1.93) 0.20 52 0.96 (0.67 to 1.37) 0.82
Polyphene
Probably damaging missense 7 7 3.39 (1.16 to 9.94) 0.026 6 1.80 (0.60 to 5.40) 0.30
Possibly damaging missense 9 1 0.44 (0.06 to 3.54) 0.44 5 1.19 (0.40 to 3.60) 0.75
Benign missense 133 57 1.53 (1.07 to 2.18) 0.021 61 0.97 (0.70 to 1.36) 0.87
Sequence conservatione
High or moderatef 50 23 1.68 (0.99 to 2.85) 0.053 32 1.35 (0.85 to 2.16) 0.20
High 6 3 1.88 (0.46 to 7.63) 0.38 8 2.85 (0.98 to 8.30) 0.055
Moderate 44 20 1.66 (0.95 to 2.91) 0.076 23 1.10 (0.65 to 1.86) 0.72
Low 99 40 1.43 (0.95 to 2.16) 0.085 41 0.88 (0.60 to 1.31) 0.53
Grantham matrix scoree
High (>60) 15 10 2.38 (1.04 to 5.45) 0.039 10 1.42 (0.63 to 3.20) 0.40
Low (≤ 60) 134 55 1.46 (1.02 to 2.10) 0.039 63 1.00 (0.72 to 1.39) 0.98
Grantham matrix score/sequence conservatione
Deleterious 4 2 1.74 (0.32 to 9.64) 0.52 3 1.63 (0.36 to 7.33) 0.53
Intermediate (unclassified) 46 22 1.75 (1.02 to 3.01) 0.043 25 1.15 (0.69 to 1.91) 0.60
Neutral 99 40 1.44 (0.95 to 2.16) 0.083 44 0.95 (0.65 to 1.39) 0.78
BRCA2g
Normal/polymorphism (reference) 279 87 1 137 1
Definitely disease-causing variant 11 13 3.69 (1.57 to 8.68) 0.003 10 1.83 (0.76 to 4.42) 0.18
Unclassified variant 462 162 1.07 (0.79 to 1.46) 0.66 213 0.93 (0.72 to 1.21) 0.59
Unclassified variant classification using
Allele frequency
High risk (LFUV) 71 18 0.81 (0.45 to 1.45) 0.48 40 1.15 (0.74 to 1.78) 0.54
Low risk (HFUV) 385 138 1.09 (0.79 to 1.50) 0.59 168 0.88 (0.67 to 1.16) 0.36
Polyphene
Probably damaging missense 32 7 0.73 (0.31 to 1.74) 0.48 17 1.09 (0.58 to 2.03) 0.79
Possibly damaging missense 108 28 0.79 (0.48 to 1.29) 0.34 42 0.78 (0.52 to 1.18) 0.24
Benign missense 310 118 1.15 (0.83 to 1.60) 0.41 146 0.95 (0.72 to 1.26) 0.73
Sequence conservationeAvailable online http://breast-cancer-research.com/content/10/1/R19
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for BRCA2 DDCV carriers is not as early as for BRCA1 DDCV
carriers [29]. In our study, the median ages were 40 and 45
years for BRCA1 and BRCA2 DDCV carriers, respectively.
Homozygous deleterious mutations in BRCA1/BRCA2  are
lethal [39-42]. In the present study, all of the low-risk UVs clas-
sified using the allele frequency method (except those that
were common only in African-Americans) were observed as
homozygous and therefore should be benign. Consistent with
this, all our low-risk UVs (HFUVs) that have been classified by
the BIC were assessed as clinically nonimportant. On the con-
trary, quite a few variants classified by the BIC as nonimpor-
tant are rare variants, and are therefore classified as high-risk
UVs (LFUVs) in our study. If a variant has arisen very recently,
its population frequency will be low even though the variant is
not clinically important [43]. The allele-frequency method may
therefore be better for the purpose of describing low-risk UVs
than high-risk UVs.
The GMS is a pairwise comparison of the two substituted
amino acids, and it has been argued that a multiple compari-
son – that is, a comparison of the substituted amino acids tak-
ing into account the natural variation of the substituted site
across species – would provide better information [44,45].
One method of achieving such a multiple comparison is to use
the integrated method of Abkevich and colleagues [26]. In our
study, however, this method was not an improvement over the
individual application of the two methods.
The Polyphen algorithm compares homologous sequences for
conservation and examines the structural and physicochemi-
cal aspects of the substitution. We found that the high-risk UV
carriers identified using Polyphen had the highest odds ratio of
first-degree family history among those identified using all
other methods. We also found that the number of clinically
nonimportant variants that were classified as high risk or
medium risk was smallest when using Polyphen. The Polyphen
algorithm has been reported to have the smallest false-positive
rate among the various online algorithms, including SIFT [35].
Polyphen has previously not been applied for BRCA1/BRCA2
whereas SIFT has been adopted for BRCA1 [24,25]. Our
results suggest that Polyphen might be useful to identify high-
risk UVs, especially when the UV has never been reported
and/or clinical information is not available.
Efforts to classify UVs are accumulating: several groups have
used simple combinations of sequence conservation and the
severity of amino acid substitutions [24-26]. Whether the clas-
sification is clinically valid, however, has not been systemati-
cally examined [26]. Other studies have used extensive
multifactorial models, most of them focusing on a few BRCA1
UVs. These models incorporate several approaches used in
this study as well as clinical characteristics [46], co-occur-
rence with deleterious mutations [19,46], and histopathologi-
cal information [19]. While clinical and co-occurrence
information has provided strong evidence to classify UVs
[37,46], however, such information is not always available,
especially for UVs that have not been reported before. Further,
High or moderate 157 42 0.80 (0.52 to 1.23) 0.31 61 0.78 (0.55 to 1.12) 0.18
High 96 30 0.92 (0.56 to 1.51) 0.75 41 0.86 (0.57 to 1.31) 0.48
Moderate 61 12 0.61 (0.31 to 1.21) 0.15 20 0.66 (0.38 to 1.14) 0.13
Low 292 113 1.18 (0.84 to 1.65) 0.33 142 0.98 (0.74 to 1.31) 0.91
Grantham matrix scoree
High (>60) 450 155 1.05 (0.77 to 1.43) 0.76 205 0.92 (0.71 to 1.20) 0.53
Low (≤ 60) 9 3 0.98 (0.25 to 3.85) 0.98 5 1.11 (0.37 to 3.39) 0.85
Grantham matrix score/sequence conservatione
Deleterious 124 34 0.83 (0.52 to 1.31) 0.42 51 0.83 (0.56 to 1.22) 0.34
Intermediate (unclassified) 66 14 0.67 (0.35 to 1.27) 0.22 28 0.87 (0.53 to 1.41) 0.56
Neutral 259 107 1.24 (0.89 to 1.75) 0.21 124 0.97 (0.72 to 1.30) 0.82
OR, odds ratio; CI, confidence interval; LFUV, low-frequency unclassified variants; HFUV, high-frequency unclassified variants. aTwenty-two and 
55 women with unknown BRCA1 and BRCA2 status were included as a separate category for corresponding analyses. Numbers do not add up 
when further classifying unclassified variants (UVs) using the classification methods since the UV carriers who had missing values for higher-risk 
UV categories could not be categorized into high-risk or low-risk groups and thus were added to the unknown group. bFamily history of breast 
cancer or ovarian cancer is the outcome (no family history (reference), first degree, and second degree). Family history unknown cases were 
deleted from the analysis. All analyses were adjusted for age at diagnosis (<35 years, 35 to <40 years, 40 to <45 years, 45+ years). cBased on 
the chi-square test. dWhen analyzing BRCA1, the model was further adjusted for the BRCA2 mutation status (definitely disease-causing variant, 
non-definitely disease-causing variant, unknown). eSplice/inframe deletion carriers of BRCA1 were excluded when analyzing BRCA1. Splice/
inframe deletion carriers of BRCA2 were excluded when analyzing BRCA2. fNumbers do not add up due to one additional subject classified after 
combining the high and moderate groups who was in the unknown BRCA1 status before combining. gWhen analyzing BRCA2, the model was 
further adjusted for BRCA1 mutation status (definitely disease-causing variant, non-definitely disease-causing variant, unknown).
Table 3 (Continued)
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it has been suggested that these "ideal" criteria cannot clas-
sify the majority of the UVs [37]. The classification methods
used in the present study may serve as "readily available" addi-
tional information to classify Uvs.
Conclusion
The present study suggests that the application of different
methodologies such as allele frequency, Polyphen, the GMS,
and sequence conservation may be useful for evaluating UVs,
especially when little functional or clinical data are available.
While we found high correlations between these classification
methods, our study suggests that each method has different
levels of false-positives and false-negatives. The Polyphen
algorithm appeared more appropriate in identifying high-risk
variants whereas the allele frequency may be useful in classi-
fying high-frequency variants as nonimportant. Although our
study does not directly address the question of whether each
specific UV is associated with the risk of breast cancer, our
results suggest that these methods could be helpful in under-
standing the significance of a UV especially when other clinical
or genetic information is not available. Further, the application
of these methods may help to prioritize UVs for further func-
tional or familial study.
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G1529R, H2116R, T2515I, A2717S, V2728I, S2835P, E2856A, 
T3013I)
Low risk (HFUV) 2 (I379M, D693N) 6 (N372H, N289H, L929S, N987I, N991D, T1414M)
Polyphen
High risk (probable) 0 3 (N987I, C1290Y, G1529R, H2116R)
Medium risk (possible) 1 (I379M) 8 (N289H, N372H, S384F, D596H, S976I, D1420Y, T2515I, 
E2856A)
Low risk (benign) 2 (D693N, 1200H) 9 (S326R, T598A, L929S, N991D, T1414M, A2717S, V2728I, 
S2835P, T3013I)
Sequence conservation
High risk (high conservation) 1 (I379M) 4 (N289H, D596H, G1529R, E2856A)
Medium risk (moderate conservation) 1 (Q1200H) 10 (S326R, T598A, V2728I, S384F, S976I, N987I, C1290Y, D1420Y, 
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T1414M, D1420Y, G1529R, T2515I, A2717S, S2835P, N987I, 
E2856A, T3013I)
Low risk (≤ 60) 2 (I379M, D693N) 4 (T598A, N991D, H2116R, V2728I)
Grantham matrix score/sequence conservation
High risk (deleterious) 0 7 (N289H, D596H, L929S, N987I, 1420Y, G1529R, E2856A)
Medium risk (unclassified) 2 (I379M, 1200H) 7 (S326R, S384F, S976I, H2116R, T2515I, A2717S, T3013I)
Low risk (neutral) 1 (D693N) 7 (N372H, T598A, N991D, C1290Y, T1414M, V2728I, S2835P)
LFUV, low-frequency unclassified variants; HFUV, high-frequency unclassified variants.Available online http://breast-cancer-research.com/content/10/1/R19
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